

1 **Title: Varying conjunctival immune response adaptations of house finch populations to a rapidly
2 evolving bacterial pathogen**

3 Authors: Nithya Kuttiyarthu Veetil¹, Amberleigh E. Henschen², Dana M. Hawley³, Balraj Melepat¹,
4 Rami A. Dalloul⁴, Vladimír Beneš⁵, James S. Adelman^{2#} and Michal Vinkler^{1#*}

5 Addresses:

- 6 1) Charles University, Faculty of Science, Department of Zoology, Viničná 7, 128 43 Prague,
7 Czech Republic, EU
- 8 2) The University of Memphis, Department of Biological Sciences, 3720 Alumni Ave, Memphis,
9 TN 38152, USA
- 10 3) Virginia Tech, Department of Biological Sciences, Blacksburg, VA 24061, USA
- 11 4) The University of Georgia, Department of Poultry Science, Athens, GA 30602, USA
- 12 5) European Molecular Biology Laboratory (EMBL), Genomics Core Facility, Meyerhofstraße 1,
13 69117 Heidelberg, Germany, EU

14 # These authors contributed equally

15 * Author for correspondence: Michal Vinkler, e-mail: michal.vinkler@natur.cuni.cz, tel.:
16 +420221951845

17 Correspondence address: Michal Vinkler, Charles University, Department of Zoology, Viničná 7, 128
18 43 Prague, Czech Republic, EU

19 **Abstract**

20 Pathogen adaptations during host-pathogen co-evolution can cause the host balance between immunity
21 and immunopathology to rapidly shift. However, little is known in natural disease systems about the
22 immunological pathways optimised through the trade-off between immunity and self-damage. The
23 evolutionary interaction between the conjunctival bacterial infection *Mycoplasma gallisepticum* (MG)
24 and its avian host, the house finch (*Haemorhous mexicanus*), can provide insights into such adaptations
25 in immune regulation. Here we use experimental infections to reveal immune variation in conjunctival
26 tissue for house finches captured from four distinct populations differing in the length of their co-
27 evolutionary histories with MG and their disease tolerance (defined as disease severity per pathogen
28 load) in controlled infection studies. To differentiate contributions of host versus pathogen evolution,
29 we compared house finch responses to one of two MG isolates: the original VA1994 isolate and a more
30 evolutionarily derived one, VA2013. To identify differential gene expression involved in initiation of
31 the immune response to MG, we performed 3'-end transcriptomic sequencing (QuantSeq) of samples
32 from the infection site, conjunctiva, collected 3-days post-infection. In response to MG, we observed an
33 increase in general pro-inflammatory signalling, as well as T-cell activation and IL17 pathway
34 differentiation, associated with a decrease in the IL12/IL23 pathway signalling. The immune response
35 was stronger in response to the evolutionarily derived MG isolate compared to the original one,
36 consistent with known increases in MG virulence over time. The host populations differed namely in
37 pre-activation immune gene expression, suggesting population-specific adaptations. Compared to other
38 populations, finches from Virginia, which have the longest co-evolutionary history with MG, showed
39 significantly higher expression of anti-inflammatory genes and Th1 mediators. This may explain the
40 evolution of disease tolerance to MG infection in VA birds. We also show a potential modulating role
41 of BCL10, a positive B- and T-cell regulator activating the NFKB signalling. Our results illuminate

42 potential mechanisms of house finch adaptation to MG-induced immunopathology, contributing to
43 understanding of the host evolutionary responses to pathogen-driven shifts in immunity-
44 immunopathology trade-offs.

45 **Running title: House finch populations vary in immune responses to *Mycoplasma***

46 **Key words:** Adaptations diversifying populations, emerging disease, coevolution, parasite, host-
47 pathogen interaction, inflammatory immune response, resistance, tolerance to infection

48 **Introduction**

49 Host-parasite co-evolution belongs among the most dynamic evolutionary phenomena (1). Novel
50 adaptations rapidly shift pathogen virulence [i.e. pathogen damage to host fitness (2)] as well as host
51 immune defence capacities. Given the frequent emergence of novel zoonotic infections transmitted to
52 humans from wildlife, there is urgent need for improved understanding of the natural variation in both
53 patterns and mechanisms of host-pathogen evolution (3,4). Despite common expectation that long-term
54 coevolution between hosts and their pathogens favours decrease in the pathogen virulence (1), present
55 evidence suggests variation in these evolutionary patterns, with long-term increase in virulence observed
56 in certain contexts (5). In response, hosts can rapidly adjust their resistance, i.e. evolve capacity to
57 decrease pathogen replication, consistent with the arms-race model (1). Such adaptations have emerged,
58 for example, in amphibians (6) and bats (7) challenged by fungal pathogens, or rabbits facing myxoma
59 virus epidemics (8). However, if pathology caused by the excessive immune defence is too costly (9),
60 the immunity-immunopathology trade-off can favour the evolution of tolerance to the infection instead
61 of, or in addition to, resistance (10–12). Unlike resistance, tolerance mitigates the host's fitness loss
62 through a reduction of tissue damage caused by infection or improved repair of this damage, without
63 necessarily reducing pathogen replication. In contrast to resistance, evolution of tolerance to infection
64 typically does not promote the arms race accelerating further increase in pathogen virulence (13,14).
65 However, if the increase in host's tolerance decreases immunopathology that favours pathogen
66 transmission, pathogen can respond by evolving higher virulence (15,16). This can further select on
67 optimisation of the immune response, setting equilibrium between host immunity and immunopathology
68 (9). Although recent research in different species of wild vertebrates (17–19) indicated that infection
69 tolerance can be a common strategy to reduce the fitness costs in hosts facing novel pathogens, we still
70 mostly lack evidence on the immunological mechanisms responsible for the shifts between resistance to
71 tolerance in natural host-pathogen systems.

72 One of the few relevant vertebrate models for this investigation where we have evidence for tolerogenic
73 adaptation (20) can be found in the recent evolutionary interaction between the bacterium *Mycoplasma*
74 *gallisepticum* (MG) and its novel host, the house finch (*Haemorhous mexicanus*) (21). MG is a
75 horizontally transmitted pathogen that shows high antigenic variation (22). Previously known to be a
76 respiratory pathogen of domestic poultry (23), in 1994 MG was first detected in wild house finches in
77 Virginia (eastern USA), causing mild to severe conjunctivitis (24). Within three years, the infection
78 spread across eastern North American populations of the host and, after a few-year's lag, in the early
79 2000s the disease was detected in western North American house finch populations (25). Mycoplasmal
80 conjunctivitis disease decreases survival of finches (26) in the wild, often causing severe decrease (up
81 to 60%) in affected house finch populations (27). However, the epizootic did not reach some isolated
82 house finch populations, such as those introduced to the Hawaiian Islands which still remain naïve to
83 MG. Further, because of the way that MG spread west across the northern part of the United States and
84 then down the western coast, MG has only recently (or in some cases, never) been documented in host
85 populations in areas of the southwest United States such as Arizona (28).

86 The house finch-MG model system is unique in avian evolutionary ecology given the precisely mapped
87 spatiotemporal epizootic data and the wealth of pathogen isolates collected throughout time from various
88 wild house finch populations that are presently available for infection experiments (29). This
89 experimental research has shown that MG virulence has increased over time, with the evolutionarily
90 original MG isolates (e.g. the isolate VA1994) causing milder disease than the more recent,
91 evolutionarily derived isolates (e.g. the isolates NC2006 or VA2013) (30,31). At the same time, there is
92 inter-individual variability among hosts in their responses to the pathogen (32) and the host populations
93 appear to have adapted to the MG selective pressure (33). We have recently shown that house finch
94 populations with a longer co-evolutionary history with MG show more tolerance to the infection than
95 the populations in recent or no contact with the pathogen (20), with tolerance quantified as milder
96 disease severity (i.e., conjunctivitis) at a given pathogen load. This is probably linked to regulation of
97 the inflammatory response, which is less pronounced in the Harderian glands of house finch populations
98 in longer contact with the pathogen, compared with populations with little or no contact with MG
99 (20,33).

100 Bacteria of the genus *Mycoplasma* are extracellular and intracellular parasites known in vertebrates to
101 trigger excessive proinflammatory signalling (e.g. mediated by *IL1B* or *IL6*), while down-regulating
102 regulatory signals with anti-inflammatory effects (e.g. *IL10*) (34). In humans, clinical manifestations of
103 acute mycoplasmosis result from immunopathologic inflammation generated by the host, rather than by
104 the direct pathogen-mediated tissue damage (35). Excessive inflammation may contribute to MG's
105 ability to evade the host effector antibody response by disrupting regulation of the inflammation,
106 improving pathogen transmission efficiency (36). In house finches, MG infection affects mainly the
107 sites belonging to conjunctiva-associated lymphoid tissue, including conjunctiva and Harderian gland
108 (37). Since its emergence in finches, MG appears to have evolved to trigger stronger pro-inflammatory
109 cytokine levels in the host periocular lymphoid tissues, which is positively correlated with increased
110 bacterial loads (37), disease severity (38), and pathogen spreadability (36). This promotes in the host an
111 evolutionary trade-off between selection on stronger immunity to clear the pathogen infection,
112 consistent with resistance, and constraint emerging from immunopathology, selecting on down-
113 regulation of inflammation achieved through tolerance.

114 Transcriptomic analysis is an important approach to identify possible shifts in immune regulation of
115 host-pathogen interactions. Previous studies using transcriptomics in house finches focused on gene
116 expression changes in spleen, a secondary lymphoid tissue not topologically linked with the MG
117 infection site where the primary direct contact between the host and the pathogen occurs (39,40). Our
118 previous RNA-seq transcriptomic research in the Harderian gland (20), a periocular secondary lymphoid
119 tissue, has shown that 3 days post inoculation (DPI) with MG, house finches from more tolerant
120 populations (those with a longer history of MG endemism) also showed reduced up-regulation of
121 immune gene expression, notably among inflammation-regulating chemokines (20). Here we adopted
122 the 3'-end transcriptomic QuantSeq approach to more closely explore the variation in immune regulation
123 underlying the observed differences between the house finch populations in their tolerance to MG.
124 Unlike the previously studied Harderian gland, conjunctiva is a lymphoid tissue directly exposed to the
125 MG pathogen and thus the first tissue to be immunologically affected by the infection. Our objective
126 was to describe the conjunctival immune response involved in directing the subsequent pathway
127 regulation towards resistance or tolerance to MG. We used samples from the same birds for which
128 Harderian gland tissues were analysed in Henschen et al. (20). MG-naïve house finch juveniles that were
129 captured in one of four wild populations (Virginia = VA, Iowa = IA, Arizona = AZ and Hawaii = HI)
130 were exposed to one of two MG isolates (original VA1994 or evolved VA2013) under controlled captive
131 conditions. At the time of experimentation, the VA population had experienced the longest coevolution

132 with MG (>20 years), the IA population only a slightly shorter co-evolution with MG than VA (~20
133 years; (24), while in AZ the MG epidemics are still relatively recent (0-5 years, with no detections in
134 the population sampled; (28), and the HI population is likely entirely naïve to MG due to its geographic
135 isolation (20). Differences between house finch populations in their co-evolutionary time with MG
136 allowed us to track the variation in the immune responses associated with adaption to the pathogen. The
137 immune responses were assessed 3 DPI in order to describe the initial phase of the infection, during
138 which innate immune regulation is being established at the infection site (37). Using differential gene
139 expression (DGE) analysis, we first identified the immune pathways involved in response to MG and
140 their differences between the four host populations (model 1). In our analysis, we focused namely on
141 the variation in pro-inflammatory pathways that could promote resistance to MG and regulatory
142 mechanisms that could increase tolerance to MG, indicating house finch adaptations to the pathogen.
143 Second, we described differences between the four host populations in control individuals, where
144 variation in baseline immune regulation can be identified (model 2). Third, we characterised differences
145 in conjunctival immune responses associated with MG strain virulence (model 3).

146 Materials and methods

147 Experimental design and animals

148 Details of the experiment are provided in (20), so here we recapitulate it only briefly. Hatch-year house
149 finches (identified as first-year based on plumage characteristics) were captured using mist nets and
150 feeder traps (41) between June and September 2018 in Blacksburg, Virginia (VA), Ames, Iowa (IA),
151 Tempe, Arizona (AZ) and Oahu, Hawaii (HI) (details provided in Table S1, Electronic Supplementary
152 Material 1, ESM1 and map displaying the details of sample collection is shown in Supplementary Figure
153 1, Fig. S1 in ESM2). Any finches that showed clinical signs of MG infection during capture were
154 immediately released. Following capture, each bird received a uniquely numbered aluminium leg band,
155 and an electronic balance was used to determine its mass. To eliminate ectoparasites, the birds were
156 all dusted with 5% sevin powder. The trapped birds were brought to the Iowa State University animal
157 facility. After arrival, all birds were subjected to an acclimation and quarantine period (minimum of 40
158 days), which included treatment with prophylactic medications to prevent naturally occurring infections.
159 A serological assay was run on blood collected approximately two weeks post-capture to ensure that all
160 birds used in experiments were seronegative for MG infection (20).

161 Birds were kept individually in medium flight cages (76 cm x 46 cm x 46 cm) for the duration of the
162 experiment and were provided *ad libitum* access to water and food. The diet consisted of a 20:80 mixture
163 of black oil sunflower seeds and pellets (Roudybush Maintenance Nibbles; Roudybush, Inc., Woodland,
164 CA). Temperatures (~22°C) and light-dark cycles (12h:12h) were kept constant.

165 The infection experiment was performed in October 2018 on a sample of 60 individuals representing
166 the four different house finch populations (VA, IA, AZ, HI). For each population, 5 individuals served
167 as controls (C) treated with Frey's media with 15% swine serum alone, 5 were treatment individuals
168 inoculated with the original MG isolate VA1994, and 5 were inoculated with the evolved MG isolate
169 VA2013 (in both treatments the MG dose was 7.5×10^6 colour changing units, CCU/mL) following the
170 same methodology as in (5,42). Three days post-infection (3 DPI), the birds were euthanised by rapid
171 decapitation and a panel of nine tissues were collected. All tissues were submerged into RNA later
172 protectant within 15 minutes of euthanasia and immediately refrigerated at 4°C. The cooled periocular
173 conjunctiva-associated lymphoid tissue (conjunctiva and nictitating membrane) samples were
174 transported within 48 hours to Charles University, Czech Republic, where they were kept frozen to -
175 80°C until further processing.

176 *RNA extraction and sequencing*

177 Our conjunctival samples contained both the conjunctiva-associated lymphoid tissue (CALT) and skin
178 of the eye lid. For ensuring the proper RNA extraction of the lymphoid tissue, we used the following
179 protocol. All conjunctival samples from the 60 birds were homogenized using PCR-clean beaded tubes
180 (OMNI International, USA - Serial Number: 2150600) using the MagNa Lyser (Roche, Basel,
181 Switzerland). The skin tissues present in the samples were separated during the centrifugation step and
182 discarded, while the homogenised lymphoid tissue was used for the total RNA extraction with the High
183 Pure RNA Tissue Kit (Roche, Basel, Switzerland). We used Nanodrop (NanoDrop ND-1000) and
184 Agilent 2100 Bioanalyzer with nano chip (Agilent Technologies, California, USA) to calculate the RNA
185 yield (in all cases >20 ng/ul) and integrity (in all cases RIN values >7) (details provided in Table S2,
186 ESM1).

187 To perform sufficiently deep transcriptomic sequencing in a representative sample of individuals with
188 different treatments across four populations, we adopted the 3'-end transcriptomic QuantSeq approach,
189 which is more cost-efficient in larger population samples than the classical RNA-seq (43–45;
190 Kuttiyarthu Veetil et al. in prep.). The library preparation and sequencing were performed at the
191 European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. All the samples were first
192 barcoded with Illumina TruSeq adapters (46). The QuantSeq libraries were prepared using Lexogen
193 QuantSeq 3'-polyadenylated RNA Library Prep Kit FWD (Illumina). The sequencing was carried out
194 using the Illumina NextSeq 500 platform. QuantSeq is based on a protocol devoid of mRNAs
195 fragmentation before reverse transcription (47), but the read fragment sequencing targets are generated
196 close to the polyadenylated 3' end. This method uses total RNA as an input and there is no prior poly(A)
197 enrichment or rRNA depletion. QuantSeq generates only one read fragment per transcript, and the
198 number of reads mapped to a given gene is, therefore, proportional to its expression (43). Eight samples
199 failed during library preparation and were excluded from the sequencing. The rest of the 52 indexed
200 samples were pooled together and single-end 80 bp reads were generated. Thus, the final analysis is
201 based on the sequence data representing conjunctival samples from 52 birds (details on the birds
202 provided in Table S3, ESM1).

203 *Transcriptomes*

204 On average, we obtained ~10 million reads per sample, comparable to zebra finch 3'-end transcriptomic
205 sequencing. The bioinformatic analysis was carried out using BAQCOM pipeline
206 (<https://github.com/hanielcedraz/BAQCOM>). The samples were aligned to the zebra finch genome
207 downloaded from Ensembl (48) (bTaeGut1_v1.p-GCA_003957565.1). The tools included
208 Trimmomatic (version 0.39)(49) for the adapter trimming, STAR software (50) for the aligning with the
209 reference and featureCounts from the Subread package (51) for assigning of the sequences and gene
210 level quantification. The alignment percentage of the conjunctiva samples to the reference genome
211 ranged between 52.42% to 80.62% (Table S4, ESM1). Next, the DGE analysis was performed using
212 the limma (Linear Models for Microarray Data) package (52) in R (version- version 4.1.1) (53). In this
213 analysis, we considered the source population, sex, and MG treatment as fixed factors, testing them
214 together with their interactions at the significance level of padj value ≤ 0.05 and a minimum log2fold
215 change value ≥ 1 . After the differential gene expression analysis, each gene in each transcriptome was
216 annotated. Ensembl BioMart (48) was used to assign gene functional annotations (geneontology, GO),
217 which were then manually supplemented with Uniprot annotations. In cases where gene names were not
218 directly available, an orthologue search was performed (Ensembl and NCBI Blast) for human
219 annotations and gene names were selected if the closest hit showed at least 60% sequence identity. We
220 used ShinyGO (version-0.77) (54) for generating the figures for pathway analysis and using Venn
221 (<https://bioinformatics.psb.ugent.be/webtools/Venn/>) to create the venn diagrams. The transcriptomic

222 sequenced data were submitted to the NCBI Sequence Read Archive. As an alternative, guided by our
223 research question, literature search (55) and previous results (33), we selected the following target
224 cytokine and receptor genes potentially involved in regulation of the house finch immune interaction
225 with MG: *IL1B*, *IL10*, *IL6*, *CXCL8*, *IL22*, *TNFSF15*, *TLR4*, *TLR3*, *TLR2*, *ACOD1*, *CSF1R*, *CCL4*, *IL18*,
226 and *TLR7* (selected based on literature search and 3' end annotation availability; Table S11, ESM1).

227 *Statistical analysis*

228 To identify potential transcriptomic groupings of our four populations, we first performed two Between
229 group analyses (BGA) using made4 package in R (56). In the first analysis, we used the individual
230 population identities as a grouping factor, while for the second analysis we adopted the distinction
231 between eastern populations (VA and IA), which share a long co-evolutionary history with MG, and
232 western (AZ and HI) populations which share a short (0-5 year) co-evolutionary history with MG, as
233 applied in our previous research (20). BGA targets the between-group variability by executing a
234 principal component analysis (PCA) on group means.

235 Next, we adopted three different methodological strategies to reveal the transcriptomic variation
236 between the house finch populations and the two MG isolates using limma package from R. Limma
237 employs moderated t-statistics to assess differences in expression of individual genes across the
238 transcriptome. It allows to design multiple-factor matrices (e.g., different time points, experimental
239 conditions, batch effects) and covariates, from which it calculates the differential gene expression by
240 accounting all the variables. Limma generates a full list of genes with associated p-values and false
241 discovery rate (FDR) for each gene, indicating the result reliability (52).

242 First, to reveal population-specific variation in immune responses to MG among the four house finch
243 populations, in the whole dataset we tested the following linear model, considering population of origin,
244 sex, MG treatment and the interaction between population and MG treatment as explanatory variables
(model 1):

246 $(\sim \text{Population} + \text{Sex} + \text{MG_treatment} + \text{Population : MG_treatment} + \text{MG_treatment : Sex}).$

247 The target-gene analysis was performed only using the whole dataset. To normalize the target gene
248 expression data, we first divided the total number of reference-aligned reads by the total number of reads
249 in the sample (C_n). To scale the data, we then multiplied each of the normalized read counts by 10
250 million (approx. 10 million was the average number of reads per sample in our dataset). Given large
251 number of zero expression levels detected, we could not make relative quantification of the expression
252 and, therefore, the variation in gene expression is shown as a logarithm of the scaled-normalized read
253 counts, with uniform scaling across all genes. These gene expression levels were visualised using
254 heatmap: pheatmap package in R.

255 Since the results of model 1 indicated limited Population:MG_treatment interactions, but revealed main
256 effects of the populations, to understand the pre-existing variation in gene expression among those
257 populations we then run a second linear model, where in the control individuals alone we tested the
258 parameters of population, sex and their interaction (**model 2**):

259 $(\sim \text{Population} + \text{Sex} + \text{Population : Sex}).$

260 Third, to reveal the differences in immunity activation caused by the two MG isolates used (the original
261 VA1994 vs. evolved VA2013), we finally separately analysed the DGE in the VA2013 treatments
262 compared to the controls, and in the VA1994 treatments compared to the controls, later contrasting the
263 two sets of results (**model 3**):

264 (~ Population + MG_treatment + Population : MG_treatment).

265

266 **Results**

267 First, to identify general transcriptomic similarities between birds from different populations, we
268 performed the between-group analyses (BGA) comparing individual populations and their western and
269 eastern sets. These did not reveal any clear grouping of the individuals based on their transcriptomic
270 profiles ($P>0.05$; Fig. S2 and Fig. S3, ESM2). To investigate variation among house finch populations
271 in their responsiveness to MG infection, we first performed a general analysis on the whole dataset
272 (model 1). In total we identified 1228 DEGs (Fig. 1; Table: 1; heatmap is provided in Fig. S4, ESM2).
273 Among the 23 genes which were differentially expressed between sexes, none showed any interaction
274 with the MG treatment, and none were involved in immunity, indicating no sex-specific variation in
275 immune responses to MG in the conjunctival gene expression. Therefore, sex effects were not further
276 considered in our analysis.

277 Regardless of the MG treatment status, compared to the VA population, most DEGs were observed in
278 the IA population (464), indicating baseline differences between these two populations in conjunctival
279 gene expression. Though high number of DEGs were detected between both the MG treatments and
280 controls (548 for VA1994 and 772 for VA2013), there was little interaction between MG treatment and
281 house finch population origin (Table 1). To indicate the overlaps between the populations and MG
282 treatments, we provide the UpSet plot in Fig 1. Among the 154 genes on the overlap of all groups, the
283 majority of the genes were lacking any annotations (representing novel transcripts) and there were no
284 genes annotated with any immune function.

285

286

287 **Table 1.** Results of the general differential gene expression (DGE) analysis for conjunctival tissue
288 collected 3 days post inoculation with *Mycoplasma gallisepticum* (MG) treatment (model 1). The table
289 shows the total numbers of differentially expressed genes (Total DEG) and the total numbers of
290 differentially expressed immune genes (Immune DEG) across different comparisons as well as numbers
291 of up-regulated (Up) and Down-regulated (Down) genes for the two infection treatments (VA1994 and
292 VA2013) compared to controls and the populations Arizona (AZ), Hawaii (HI) and Iowa (IA) when
293 compared to the Virginia (VA) population, including interactions.


294

Factors	Total DEG	Total Up	Total Down	Immune DEG	Immune Up	Immune Down
AZ	309	141	168	17	15	2
HI	431	151	280	29	24	5
IA	464	131	333	18	15	3
VA1994	548	310	238	76	71	5
VA2013	772	444	328	91	81	10
AZ:VA1994	5	0	5	0	0	0
AZ:VA2013	1	0	1	0	0	0
HI:VA1994	6	2	4	2	0	2
HI:VA2013	2	0	2	1	0	1

IA:VA1994	1	0	1	1	0	1
IA:VA2013	0	0	0	0	0	0
SEX	23	15	8	0	0	0
VA1994:SEX	0	0	0	0	0	0
VA2013:SEX	0	0	0	0	0	0

295

296



297

298 **Figure 1.** UpSet plot depicting the common differentially expressed genes in conjunctival tissue across
 299 the investigated house finch populations and the *Mycoplasma gallisepticum* (MG) treatments. The house
 300 finch populations namely, Arizona (AZ), Iowa (IA) and Hawaii (HI) are compared with the Virginia
 301 (VA) population, the MG treatments (VA1994 and VA2013) are compared with the controls. The gene
 302 set size is represented by the bar height, and the population-treatment interaction by the lines connecting
 303 the main category dots.


304

305 While we identified in total 900 DEGs related to MG infection (across all population, combining
 306 VA1994 and VA2013, with the main effects and interactions), only 793 were annotated (Table S5,
 307 ESM1), and among those we identified 113 DEGs involved in immunity (Table S6, ESM1). There were
 308 158 annotated DEGs down-regulated in their expression during MG infection. For example, *CHRN B2*,
 309 *ATP2B1*, *SCN2A*, *RYR2*, *NKAIN1* and *CACNA1C* are important for the ion transport [GO:0006811],
 310 synaptic signalling [GO:0032225] and response to muscle activity [GO:0014850] (Fig. S5, ESM2). Only
 311 11 out of the 158 down-regulated genes showed clear links to immunity, including *IL12B* and *RAG1*
 312 that are involved in Th1/Th17 immune response activation [GO:0032735, GO:0032740], positive
 313 regulation of T cell differentiation [GO:0045582], pre-B cell allelic exclusion [GO:0002331] and
 314 adaptive immune response [GO:0002250]. Among the 457 annotated DEGs up-regulated during MG

315 infection, we were able to identify 91 genes with immune function. In the MG-treated individuals, we
316 observed increased expression of, e.g. *IL17RA* and *IL17RE* involved in inflammatory response
317 [GO:0050729], regulation through IL17-mediated signalling pathway [GO:0097400], *CXCL12* involved
318 in defence response [GO:0006952], *TLR1B* activating toll-like receptor TLR6:TLR2 signaling pathway
319 [GO:0038124], a leukocyte marker *PTPRC(CD45)* regulating T cell proliferation [GO:0042102],
320 *ACOD1* involved in positive regulation of antimicrobial humoral response [GO:0002760] and negative
321 regulation of the inflammatory responses (57), and *CD74* involved in antigen processing and
322 presentation [GO:0019882]. The main pathways in which the genes were up-regulated during MG
323 infection are shown in Fig 2. Interestingly, while not statistically significant, *IL22* gene that plays a
324 critical role in modulating tissue responses during inflammation [GO:0005125, GO:0006954], was
325 found to be close to significance with increased expression in the birds treated with the VA2013 isolate
326 (padj cut-off value = 0.07).

327 There were few genes for which we detected significant interactions between population and MG
328 treatment (Table S7, ESM1). Out of these, only 3 genes were involved in immune regulation. *BCL10*
329 (positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8
330 production [GO:0032757], positive regulation of NFKB transcription factor activity [GO:0051092];
331 having roles in both innate immune response [GO:0045087] and adaptive immune response
332 [GO:0002250]) was significantly differentially expressed in interaction between both HI and IA
333 population and treatment with the MG isolate VA1994. During MG infection, *BCL10* was down-
334 regulated in these populations. *CNN2* (actomyosin structure organization [GO:0031032]) and *TRIM13*
335 (innate immune response [GO:0045087]; positive regulation of cell death [GO:0010942]) were detected
336 in interaction between HI population and VA1994.

337



338

339 **Figure 2.** The gene interaction network for the differentially expressed genes (DEGs) up-regulated in
 340 conjunctival tissue 3 days post inoculation (DPI) with *Mycoplasma gallisepticum* (infected vs. non-
 341 infected birds across all house finch populations), showing the most significant pathways in the GO
 342 category Biological process. Immune genes grouped in the pathways of our interest are highlighted with
 343 red rectangles. Node colour intensity indicates significance of gene enrichment, node size indicates
 344 number of significant DEGs.


345

346 In the same analysis, a large number of DEGs were revealed between different house finch populations,
 347 regardless of the MG infection. In AZ birds, out of the 309 DEGs identified (Table S8, ESM1) we were
 348 able to annotate 106 genes with expression higher and 35 genes with expression lower than in the VA
 349 population. There were 17 genes with immune-related functions, out of which 15 genes showed higher
 350 expression in AZ than in VA, including e.g., *BCL10*, *IL17D* involved in positive regulation of
 351 interleukin-8 production [GO:0032757] and *CASP6* involved in activation of innate immune response
 352 [GO:0002218]. The main immune gene with lower expression in AZ versus VA birds was *NR1H4*
 353 involved in negative regulation of IL1 [GO:0032692] production and inflammatory response
 354 [GO:0050728]. For HI birds, we found 431 DEGs, out of which 130 annotated genes had higher and 81
 355 genes lower expression than in the VA population (Table S9, ESM1). There were 28 genes linked with
 356 immune functions, again most of them (23 genes) having higher expression in HI than in the VA
 357 population. Like in AZ, these genes included *BCL10* and *CASP6*, but also *MAST2* involved in negative
 358 regulation of IL12 production [GO:0032655]. The immune genes with lower expression in HI relative

359 to VA were *NR1H4*, *RAG1* and *KPNA6* involved in positive regulation of cytokine production involved
 360 in inflammatory response [GO:1900017]. In the IA population we found as many as 464 DEGs
 361 compared to the VA population (Table S10, ESM1), among which 114 annotated genes showed higher
 362 expression and 80 genes lower expression than in the VA population. Among the 17 genes annotated
 363 with immune function, 15 (including again *BCL10* and *CASP6*, and *TRIM13*) had higher expression and
 364 two genes (*RAG1* and *NR1H4*) lower expression in IA than in VA. Thus, our results indicate that there
 365 is important variation between the house finch populations in immune gene expression in conjunctival
 366 tissue that is independent of the actual MG treatment (no significant effect of the interaction between
 367 the MG treatment and population).

368 As an alternative approach, we also checked for the relative DGE changes in selected key immune genes
 369 with regulatory roles in immunity (target-gene analysis; Table S11, ESM1) between the control and
 370 treatment groups of birds from different populations. Our results (statistics provided in Table S12,
 371 ESM1) find that *IL1B*, *IL6*, *IL10*, *IL12B*, *IL17D*, *IL18*, *IL22*, *CCL4*, *ACOD1*, *TLR1*, *TLR4* and
 372 *TLR7* show clear distinction between the controls and the MG treatment groups (Fig. 3), and at the same
 373 time *CCL4*, *TLR1*, *TLR4*, *TLR7* show also significant variation in expression between the populations.
 374 In *TLR1*, we even detected significant interaction between the MG treatment and population (AZ, HI)
 375 indicating differences in DGE between the populations in response to MG infection.

376



380 to two types of *Mycoplasma gallisepticum* (MG)-infected treatments (VA1994 and VA2013) and
381 controls. Y-axis provides the information on individual birds (including population name and treatment
382 group); X-axis shows the gene names; colour indicates the gene expression levels shown as a logarithm
383 of the scaled-normalized read count varying from low expression (dark blue) to high expression (red).
384 Please note that the scaling is not relative and, therefore, the colour pattern is common to all genes
385 (highly as well as lowly expressed).

386

387 *Immune genes differentially expressed between populations in the unstimulated controls*

388 Since the differences between the house finch populations in expression of immune genes were largely
389 independent of MG infection status, indicating potential population-specific adaptations to MG, we also
390 checked for differences in immune regulation in the unstimulated control individuals across populations
391 (model 2). Our analysis showed 748 DEGs in the control individuals, with 71 genes (out of the 498
392 genes with defined annotations) being involved in immunity (Table: 2).

393

394 **Table 2.** Results of the general differential gene expression (DGE) analysis in conjunctival tissue of
395 control individuals (model 2). The table shows the total numbers of differentially expressed genes (Total
396 DEG) and the total numbers of differentially expressed immune genes (Immune DEG) across the
397 Arizona (AZ), Iowa (IA) and Hawaii (HI) and Virginia (VA) populations. Up = up-regulated (increased
398 expression) in the tested population compared to VA, Down = down-regulated (decreased expression)
399 in the tested population compared to the VA population.


Factors	Total DEG	Total Up	Total Down	Immune DEG	Immune Up	Immune Down
AZ	342	152	190	40	18	22
HI	270	55	215	31	8	23
IA	281	63	218	39	11	28

400

401

402 The lists of genes with lower expression in AZ, IA and HI populations compared to the VA population
403 (Table S13, ESM1) were mostly consistent (Fig. S6, ESM2), indicating generally increased expression
404 of the genes in the VA birds: out of the 31 DEGs with immune function, 19 were shared between AZ,
405 IA and HI birds. Notably, these included *LIF* (having role in regulation of immune response
406 [GO:0050776] and anti-inflammatory properties; 58), *IL12B* and *IL7* (positive regulation of T cell
407 differentiation [GO:0045582] and cytokine-mediated signaling pathway [GO:0001961]). Among the
408 184 genes (Table S14, ESM1) that were consistently expressed at higher levels in other populations
409 compared to VA, 35 genes (Table S15, ESM1) were shared between the AZ, HI and IA, indicating
410 decreased expression in the VA population. There were 25 DEGs annotated with immune function
411 which had higher expression across these three populations when compared to VA birds. Out of them,
412 however, only 4 genes were shared: *BCL10*, *GGT5* (role in inflammatory response [GO:0006954]),
413 *RABGEF1* (negative regulation of inflammatory response [GO:0050728]) and *SYNCRIP* (cellular
414 response to interferon-gamma [GO:0071346]) (Fig. 4).

415



416

417

418 **Figure 4.** The gene interaction network for the differentially expressed genes (DEGs) with higher
 419 expression in conjunctiva of control birds in Iowa (IA), Arizona (AZ) and Hawaii (HI) compared to
 420 Virginia (VA). The most significant pathways in the GO category Biological process are shown.
 421 Immune genes grouped in the pathways of our interest are highlighted with red rectangles. Node colour
 422 intensity indicates significance of gene enrichment, node size indicates number of significant DEGs.

423

424 The main uniquely up-regulated immune genes (18 genes) in the AZ population included *IL17D*, *IL17C*
 425 (inflammatory response [GO:0006954]), *IRF6* (immune system process [GO:0002376]), *TLR15* (toll-
 426 like receptor signaling pathway [GO:0002224]) and *TLR1B* genes (up-regulated and down-regulated
 427 pathways are shown in Fig. S7 and Fig. S8, ESM2). In contrast to AZ, the HI and IA populations (up-
 428 regulated and down-regulated pathways for IA and HI birds, respectively, are shown in Fig. S9 and Fig.
 429 S10 and Fig. S11 and Fig. S12, ESM2) showed almost identical sets of DEGs in the control birds: out
 430 of a total of 40 DEGs with immune function revealed in these populations, 28 genes were shared between
 431 these two populations, including *TRIM13*, *PPARD* (negative regulation of inflammatory response
 432 [GO:0050728]) and *BCAR1* (antigen receptor-mediated signaling pathway [GO:0050851]) that were
 433 different from the AZ population. These genes are involved in immune pathways involved in cytokine
 434 production by mast cells and B cells.

435 *Immune genes differentially expressed between individuals inoculated with different MG isolates*

436 Our third analysis (model 3) showed only 160 DEGs for the MG VA1994 isolate, but 1229 DEGs for
 437 the VA2013 isolate (Table: 3). Considering only the genes with annotations related to immune function,
 438 there were 54 genes differentially expressed during the infection with VA1994 and 230 genes during
 439 the infection with VA2013. In birds infected with VA1994, all the differentially expressed immune
 440 genes showed higher expression when compared to control birds. In birds infected with VA2013, there
 441 were 191 genes with higher expression and 39 genes with lower expression when compared to the
 442 controls (full list of the genes is provided in Table S16 and Table S17, ESM1).

443

444 **Table 3.** Results of the differential gene expression (DGE) analysis in conjunctival tissue collected 3
 445 days post inoculation with VA1994 and VA2013 isolates of *Mycoplasma gallisepticum* (MG) analysed
 446 separately (model 3). The table shows the total numbers of differentially expressed genes (Total DEG)
 447 and the total numbers of differentially expressed immune genes (Immune DEG) for the MG isolates
 448 (Va1994 and VA2013), populations (Arizona = AZ, Hawaii = HI, Iowa = IA, Virginia = VA) and their
 449 interactions. Up = up-regulated compared to controls / increased expression in the tested population
 450 compared to VA, Down = down-regulated compared to controls / decreased expression in the tested
 451 population compared to the VA population.


Factors	Total DEG	Total Up	Total Down	Immune DEG	Immune Up	Immune Down
VA1994	160	148	12	22	22	0
AZ	6	6	0	0	0	0
HI	2	2	0	0	0	0
IA	14	11	3	0	1	0
VA1994:AZ	0	0	0	0	0	0
VA1994:HI	0	0	0	0	0	0
VA1994:IA	0	0	0	0	0	0
VA2013	1229	785	444	178	139	39
AZ	34	26	8	3	3	0
HI	45	28	17	3	2	1
IA	47	37	10	2	2	0
VA2013:AZ	2	0	2	0	0	0
VA2013:HI	2	1	1	0	0	0
VA2013:IA	1	1	0	0	0	0

452

453

454 Since the DEGs common to infections with both isolates are consistent with those already discussed in
 455 the first analysis (model 1), here we focus only on the differences between the isolates. We found 20
 456 specific genes differentially expressed on 3 DPI after inoculation with the VA1994 isolate, out of which
 457 only two genes were related with any defined immune functions: *NFATC3* and *PTAFR*, both involved
 458 in inflammation [GO:0006954] (Fig.5). For VA1994, there were no genes showing any significant
 459 interaction with the populations. The up-regulated and down-regulated gene interaction network for MG
 460 isolate VA1994 is shown in Fig. S13 and Fig. S14, ESM2.

461



462


463 Figure 5: Venn diagram showing the number of differentially expressed genes (DEGs) during infection
 464 with the original *Mycoplasma gallisepticum* (MG) isolate VA1994 and the evolved isolate VA2013.

465

466 Among the 1089 genes differentially expressed after inoculation with the MG isolate VA2013, there
 467 were 139 DEGs involved in immune function that were up-regulated, including *IL1B* (cytokine-
 468 mediated signaling pathway [GO:0019221]), *IL10* (negative regulation of cytokine activity
 469 [GO:0060302]), *IL18* (natural killer cell activation [GO:0030101]), *IL22* (inflammatory response
 470 [GO:0006954]), *TLR4* (activation of innate immune response [GO:0002218]), and *TLR7* (positive
 471 regulation of interferon-beta production [GO:0032728]) (see the pathways shown in Fig.6), and 39
 472 immune DEGs that were down-regulated, including *ILRUN* (negative regulation of defense response to
 473 virus [GO:0050687]), *NTS* (positive regulation of NFKB transcription factor activity [GO:0051092]),
 474 *ROMO1* (defense response to Gram-negative bacterium [GO:0050829]), *AKAP1* (antiviral innate
 475 immune response [GO:0140374]), involved in the innate immune response, antimicrobial humoral
 476 immune response mediated by antimicrobial peptides, defense response to bacterium and antiviral innate
 477 immune response (Figure:S15).

478 Two genes were significantly differentially expressed in VA2013 in interaction with the HI population:
 479 *CNN2* had lower expression, involved in wound healing [GO:0042060] and *YWHAZ* higher expression
 480 than in VA, having role in signal transduction [GO:0007165]. There was one gene with significant
 481 interaction between the IA population and VA2013 treatment, which is a long non-coding RNA with
 482 unknown function. For the AZ population, there were two genes with significant interaction to the
 483 VA2013 treatment, again both with unknown functions.

484



485


486 **Figure 6.** The gene interaction network for all the up-regulated differentially expressed genes (DEGs)
487 in conjunctiva 3 days post inoculation (DPI) with *Mycoplasma gallisepticum* in birds infected with
488 VA1994 versus VA2013. The network is showing the most significant pathways in the GO category
489 Biological process across all the house finch populations analysed. Immune genes grouped in the
490 pathways of our interest are highlighted in red rectangles. Node colour intensity indicates significance
491 of gene enrichment, node size indicates number of significant DEGs.

492

493 *Differentially expressed genes commonly identified across the analyses*

494 Finally, we searched for the genes that were identified as differentially expressed in all the three
495 comparisons, i.e., the 1) DEGs during MG infection, 2) different pre-activation levels of expression
496 between the populations unrelated to the MG infection, and 3) variation in expression based on the MG
497 isolate used for the infection.

498



499

500 **Figure 7.** Venn diagram showing the genes in common between all the three comparative analyses
 501 performed. We found eight genes differentially expressed in conjunctiva during *Mycoplasma*
 502 *gallisepticum* (MG) infection (model 1), with pre-activation levels that differed among the four
 503 populations (model 2), and that differed in expression in response to the different MG isolates used for
 504 the inoculation (model 3).

505

506 We identified 8 common genes (Fig.7): *BCL10* integrating innate immune response [GO:0045087] and
 507 adaptive immune response regulation [GO:0002250], *USPL1* acting in cajal body organization
 508 [GO:0030576] and cell proliferation [GO:0008283], *VPS4B* acting in autophagy [GO:0016236] and
 509 cholesterol transport [GO:0030301], *RNF114* responsible for cell differentiation [GO:0030154] and
 510 protein polyubiquitination [GO:0000209], *AFMID* involved in tryptophan metabolism to kynurenone,
 511 *ELMOD1* positively regulating the GTPase activity [GO:0019441], *CAPRIN1* responsible for negative
 512 regulation of translation [GO:0017148] and positive regulation of dendrite morphogenesis
 513 [GO:0050775] and *WDR5B* affecting histone H3-K4 methylation [GO:0051568]. Out of these genes,
 514 only *BCL10* has any clear role in immunity. However, seven immune genes were also common DEGs
 515 between the first and second analysis, i.e. involved in the response to MG and also differentially pre-
 516 activated in different populations: *IL12B* regulating cellular response to IFNG [GO:0071346] and T-
 517 helper cells differentiation [GO:0042093], *PPARD* and *NR1H4* which are negative regulators of
 518 inflammatory responses [GO:0050728], including cellular responses to lipopolysaccharide
 519 [GO:0071222], *RAG1* that is key to immunoglobulin receptor recombination conditioning adaptive
 520 immune response during T-cell B-cell differentiation [GO:0002250], *RAC2* positively affecting
 521 neutrophil chemotaxis [GO:0090023] and T-cell proliferation [GO:0042129], *TRIM13* involved in
 522 positive regulation of NFKB signaling [GO:0043123] during innate immune responses, and *NCAPH2*
 523 involved in T-cell differentiation in the thymus [GO:0033077]. Finally, three immune genes showed as
 524 DEGs common to the second and third analyses, i.e. differentially pre-activated in different house finch

525 populations and also involved in differential immune response to the two different MG isolates: *CDH17*
526 involved in B-cell differentiation [GO:0002314], *ACTG1* affecting cellular response to IFNG
527 [GO:0071346] and *ROMO1* inducing production of reactive oxygen species (ROS) [GO:0034614],
528 which is important in antimicrobial immune responses to bacteria.

529

530 Discussion

531 Using QuantSeq 3'-end RNA transcriptomic sequencing, in this study we characterised gene expression
532 changes in a house finch periocular lymphoid tissue, the conjunctiva, during the initial phase of infection
533 (day 3 post inoculation) with a naturally occurring pathogen, MG. We focused on DPI 3 as a period of
534 innate immune regulation that later guides the subsequent phases of the response either towards
535 immunopathology-linked resistance or towards tolerance. Our focus was on the DEGs involved in the
536 immune response and showing variation between the house finch populations differing in their co-
537 evolutionary history with MG, as this variation may indicate adaptations of the host to MG, including
538 in response to the increasing pathogen virulence documented previously (38). We show significant
539 variation in expression of many inflammatory genes, especially those relevant for regulation of the
540 Th1/Th17 pathways. In response to MG, gene expression is up-regulated at the infection site in
541 pathogen-recognition receptors (e.g. *TLR1B*), signalling molecules and their receptors (such as *CXCL12*
542 and *IL17R*), adaptive cell-surface receptors (*CD74*) and various other immunomodulators (e.g. *ACOD1*).
543 Several genes important for immune response regulation varied between individuals representing house
544 finch populations differing in their co-evolutionary history with MG (e.g., *IL12B*, *IL17*, *CASP6*, *NR1H4*
545 or *IRF6*). Most interestingly, our data suggest that in VA, the population with the longest co-
546 evolutionary history with MG, the birds decrease the baseline *BCL10* gene expression compared to other
547 populations (irrespective of MG infection in model 1, and only in controls in model 2). *BCL10* also
548 showed significant interactions between house finch populations and the MG treatment (model 1). In
549 our analyses, *BCL10* was revealed as up-regulated during MG infection caused by the evolved VA2013
550 isolate (model 3). This gene has important roles in NFKB signalling and activation of both innate and
551 adaptive immune responses, so down-regulation of its expression in the VA population may adaptively
552 increase tolerance to infection by minimizing damaging inflammation.

553 Previous transcriptomic research of the house finch-MG interaction suggested that the immediate
554 adaptation of the host to MG favoured increases in host resistance. Bonneaud et al. (40) found that house
555 finches from populations naïve to MG experience reduced splenic immune responsiveness to MG, while
556 the populations with a 12-year history of MG exposure (at the time of that study) have up-regulated
557 expression of genes associated with acquired immunity in the spleen 14 days post inoculation. While
558 this immune response can be eventually protective, allowing recovery, important costs are likely
559 associated with such immune response. Initial results of Adelman et al. (33) indicated that in populations
560 with longer co-evolutionary history with MG, tolerance to the infection (defined as minimizing disease
561 severity at a given pathogen load) can contribute to improving host health. Recently, this pattern was
562 confirmed by Henschchen et al. (20), who demonstrated tolerance to MG in the eastern house finch
563 populations with >20-year coevolutionary history with the pathogen. This study revealed that in the
564 Harderian glands of the same birds as used in this study, up-regulated expression of some cytokines and
565 cytokine receptors (*CXCL8*, *CXCL14*, *CCL20*, *CSF3R*) was present only in the less-tolerant populations
566 that have not yet or only recently experienced epidemics with MG (AZ, HI). In contrast to Henschchen et
567 al. (20), our transcriptomic results in conjunctiva do not indicate clear similarities in gene expression
568 patterns between birds from the eastern populations that share a long co-evolutionary history with MG
569 (VA and IA), when compared to western populations (AZ and HI). This suggests that each population

570 might have evolved a slightly different mode of regulation of the immune response to MG at the
571 conjunctival infection site.

572 Our results indicate that the immune response triggered by MG 3DPI in conjunctiva represents Th17-
573 directed inflammation. From the total 109 genes differentially expressed, the majority of immune genes
574 (91) were up-regulated, including e.g. *TLR1B* receptor activating inflammation, *IL17* receptor genes
575 *IL17RA* and *IL17RE*, chemokine *CXCL12*, but also *ACOD1*, a negative regulator of the inflammatory
576 response. These immune genes have significant and interspecifically conserved roles in immune
577 activation and regulation (59–64). Similar to our results, previous transcriptomic research in chickens
578 has also shown increases in expression of *TLR1B*, *CXCL12* and *ACOD1* after infection with MG (65–
579 67). Some genes, such as *CD74* expressed on antigen-presenting cells (68) as a receptor for macrophage
580 migration inhibitory factor (MIF) (69) inducing inflammation (70), showed patterns of expression
581 contrasting with previous research in the house finch-MG system. While our data show up-regulation,
582 Bonneaud et al. (39) reported down-regulation of *CD74* during infection. This contrast could result from
583 the difference in tissue used, the time of tissue collection post-infection, or differences in host population
584 coevolutionary time with MG when the studies were performed: the population with noted resistance in
585 Bonneaud et al. (39) had ~12 years of co-evolution with MG versus 20–25 years of MG coevolution for
586 the IA and VA populations used in this study. Increased *CD74* expression during MG infection could
587 improve activation of antigen-presenting cells (68), and through interaction with MIF (70), could also
588 promote regenerative pathways in the tissue preventing the host damage. Overall, this could contribute
589 to the observed host tolerance to MG in certain house finch populations. We found that only 11 immune
590 genes were down-regulated in conjunctival tissue in response to MG, including *IL12B*, an essential
591 mediator of the Th1 immune response. This is consistent with observations by Bonneaud et al. (40),
592 suggesting that MG may be manipulating house finch gene expression during the acute immune response
593 in order to allow efficient infection establishment. MG was revealed to cause immune suppression in
594 the initial infection stages in chickens, suppressing expression of key cytokines involved in
595 inflammation, including *IL8*, *IL12* and *CCL20* (71). Thus, our data support this hypothesis, indicating
596 that MG may be down-regulating specific host immune pathways rather than overall immune activation.

597 Contrary to our expectations and to results from Harderian gland transcriptomes in the same birds (20),
598 our general analysis of the conjunctival transcriptomes (model 1) suggested only limited interactions
599 between MG infection status and population of origin. This result indicates tissue-specific differences
600 in the immune regulation, but also that variation in the responses between populations may depend only
601 on few key modifiers of the immune regulation rather than extensive transcriptome alterations. The most
602 promising immune-controlling gene revealed in our results is *BCL10*, a positive regulator of cytokine
603 expression involved in modulation of adaptive immune responses. In mammals, *BCL10* has a vital role
604 in channelling adaptive and innate immune signals downstream to CARMA/caspase-recruitment
605 domain (CARD) scaffold proteins (72). *BCL10* oligomerization via the CARD facilitates NFKB
606 activation (73–75). Previous research in mice showed that *BCL10* is a positive regulator of lymphocyte
607 proliferation inducing antigen receptor signalling in B and T cells in response to NFKB activation (76).
608 Impairment in *BCL10* function negatively affects the development of memory B, CD4⁺ and CD8⁺ T
609 cells (77). The immunomodulatory effects of *BCL10* are further documented by the up-regulation of its
610 expression during experimental bacterial infections in cattle (78) and poultry (79). However, it has to be
611 noted that there are also additional non-immune functions of *BCL10* described in other cells, including
612 its involvement in neuronal regulation (80). Based on our data the precise role of *BCL10* in the
613 conjunctival tissue and causality of the changes in its expression cannot be inferred.

614 Although we did not find strong evidence for population differences in response to infection treatment,
615 our results showed high number of immune genes that vary in their conjunctival expression between the

616 house finch populations, independently of MG infection. These include key Th17 pathway regulators,
617 such as the cytokine *IL17D* that is known to induce expression of other pro-inflammatory cytokines,
618 including *IL6* and *CXCL8*. This may suggest population-specific adaptations in conjunctival gene
619 expression, potentially contributing to optimisation of the immune interaction with MG at the infection
620 site. *IL17* has a vital role in the initiation of chemotaxis and the functioning of Th17 cells (81,82) and
621 commonly shows up-regulation in birds immunized with various intracellular pathogens (83).
622 Conjunctiva is colonised by innate lymphoid cells (ILCs), NK cells, $\gamma\delta$ T cells (84), $\alpha\beta$ T cells (85) and
623 memory T cells (86), out of which the $\gamma\delta$ T cells were identified as the predominant source of *IL17*
624 during inflammation (87). In our study, *IL17D* was generally highly expressed in the AZ population,
625 which, together with increased *BCL10*, *CASP6* and decreased *NR1H4* (a negative regulator of *IL1B*
626 production; 88) compared to the VA birds suggests disposition of the birds to resistance-oriented
627 response through Th17 pathway pre-activation. Although the activity of *NR1H4* in conjunctiva is
628 presently not entirely clear, its function at the site may be relevant, as in the gut this receptor negatively
629 controls expression of a number of genes that activate inflammatory responses (89–91). In contrast to
630 other populations, longer co-evolutionary history with MG may have selected the VA population to
631 increase *NR1H4* and decrease *BCL10* expression, which is in agreement with the tolerance evolution
632 described in house finches by Henschen et al. (20). This view is partially supported also by our target-
633 gene analysis focusing on selected key immune genes with regulatory roles in immunity. All populations
634 up-regulated *IL1B*, *IL6*, *IL10*, *IL18*, *IL22*, *CXCL8*, *CCL4*, *TLR1*, *ACOD1*, *TLR4*, and *TLR7* when
635 infected with evolved MG (VA2013), which would propagate inflammation and facilitate pathogen
636 transmission through pathological mycoplasmal conjunctivitis (15,36). However, the AZ birds,
637 compared to VA birds, showed a particularly high increase in expression of *TLR1* and *TLR4*, probably
638 intensifying the resistance-oriented inflammatory response to MG. Our result thus shows similarity to
639 the findings of Adelman et al. (33) in which house finches from populations with a longer coevolutionary
640 history with MG (VA) showed lower inflammatory signalling and increased tolerance to infection than
641 birds from populations with recent contact history (AZ) with MG. Further research is, however, needed
642 to confirm the putative tolerogenic adaptations in the VA population.

643 Bonneaud et al. (40) proposed that the variation between house finch populations in resistance to MG
644 likely results from some adaptations changing the initial innate immune regulation directing the
645 subsequent adaptive immune response. This idea is consistent with the evidence from laboratory rodents
646 showing that the initial innate immune regulation defines the efficiency of the clearance of mycoplasmal
647 infections (92). Given the results we obtained from our general analysis (model 1), we tested this
648 hypothesis using a subset of the data representing only the control individuals from the four house finch
649 populations (model 2). From the high number of genes differentially expressed in the controls between
650 the populations, 71 genes had clear roles in immunity. Consistent with our previous result, the control
651 birds from the AZ population showed higher baseline expression of *IL17D*, *IL17C*, *IRF6*, *TLR15* and
652 *TLR1B* genes putatively strengthening the overall Th17 responses, while the VA population showed
653 stronger expression of *IL7*, *IL12B* and *LIF*, suggesting possible pre-activated Th1 immune pathway
654 coupled with anti-inflammatory signalling, which was again linked with decreased *BCL10* expression.
655 We assume that immunological regulation of tolerance to infection must involve balanced changes of
656 both pro- and anti- inflammatory pathways to prevent infection-caused mortality. *IL12B*, a subunit of
657 *IL12*, primarily stimulates natural killer (NK) cells and induces the differentiation of naive CD4⁺ T
658 lymphocytes into T helper 1 (Th1) effectors (93). If the *IL12B* subunit is dimerized with the *IL23A*
659 subunit, then functional *IL23* is produced (94), which is necessary for Th17 development and function
660 (95). Alternatively, *IL12B* can also mediate anti-inflammatory regulation increasing expression of other
661 regulatory cytokines such as *IL10* (96), with *IL7* supporting the host defence by regulating immune cell
662 growth and homeostasis (97). Thus, increased baseline expression of *IL12B* might have multiple

663 functional roles in protecting the health of the VA birds during the onset of MG infection. Birds from
664 the HI and IA populations showed similar up-regulation of immune-related pathways activated by mast
665 cells and B cells (*TRIM13* and *PPARD*) when compared with the VA birds but also with AZ birds. Taken
666 altogether, the pattern of immune gene expression in the VA birds was different from all the other three
667 remaining house finch populations, putatively resulting, at least in part, from long-lasting adaptation to
668 MG through a combination of resistance and tolerance (20).

669 We also examined pathogen contributions to differential conjunctival gene expression across
670 populations (model 3). Consistent with previous research (20,37,38) we found that the evolved
671 (VA2013) isolate triggers much stronger conjunctival immune responses than the original (VA1994)
672 one, here indicated by the number of DEGs when compared to controls. In contrast to VA1994, the
673 evolved isolate VA2013 activated pathways involving differential expression of both pro-inflammatory
674 and anti-inflammatory genes, including key signal mediators such as *IL1B*, *IL10*, *IL18*, *IL22* and *CXCL8*.
675 Especially negative regulators of inflammation, such as *IL10*, can play important roles in fine-tuning
676 immunomodulation, since their down-regulation can improve pathogen clearance, but also increase
677 tissue damage (98–101), optimising the immunity-immunopathology balance in the defence (9).
678 Previous research in rodents performed both *in vivo* and *in vitro* shows that *Mycoplasma pneumoniae*
679 antigens induce potent immune reactions through enhancement of the Th17 response, but regulatory T
680 cell (Treg) activation linked with *IL10* expression simultaneously suppress *IL17A* expression (102). In
681 contrast, *IL18* is a potent pro-inflammatory cytokine regulating both innate and acquired immune
682 responses (103). Studies in chicken show that MG infection increased mRNA levels of *IL18* between 3
683 and 7 DPI, similar to our results (104). Also *IL22* is a key mediator of inflammation that is produced
684 immediately after stimulation to initiate an immune response, mediating also mucous production, wound
685 healing, and tissue regeneration (105). Comparable to our results, *IL22* gene has been reported as up-
686 regulated during *Mycoplasma ovipneumoniae* infection in sheep (106).

687 Overall, comparison of the results from all three analyses performed identifies *BCL10* as a potentially
688 important immune gene that changes its conjunctival expression during the MG infection, varies in its
689 expression between individuals from different house finch populations, and also varies in expression
690 depending on the MG isolate infecting the birds. Furthermore, other genes involved in the response to
691 MG (model 1 or model 3) and at the same time also differentially pre-activated in distinct host
692 populations (model 2) may be of high importance for house finch adaptation to MG. Our results
693 elucidated both positive and negative regulators of inflammation and Th1 immunity, including *IL12B*
694 and possibly also *PPARD* and *NR1H4*. Roles of other genes repeatedly revealed in our analyses are less
695 clear, but they may contribute to altered leukocyte differentiation, infiltration into the tissue or cell
696 activation (*RAG1*, *RAC2*, *TRIM13*, *NCAPH2*, *CDH17*, *ACTG1* and *ROMO1*). Thus, all these 11 genes
697 potentially provide adaptations to the selective pressures posed by MG varying between the house finch
698 populations.

699 Our transcriptomic results obtained in conjunctiva apparently differ from the results obtained earlier by
700 Henschen et al. (20) from the same experiment but for a different tissue, the Harderian gland. Most
701 importantly, the pattern of variation between the house finch populations revealed for the two tissues in
702 response to MG is different. While we assume that biologically significant differences in immune
703 regulation between the tissues are responsible for the differences in gene expression patterns observed,
704 we are, unfortunately, presently unable to explain them, because for the two studies different
705 transcriptomic methods were adopted, RNA-seq and QuantSeq, respectively. The RNA-seq approach
706 can be biased by more enriched DEGs for longer transcripts than for the shorter ones (107). Previous
707 research has reported that RNA-seq identifies in general more DEGs, but QuantSeq can detect more of
708 the shorter transcripts (47) that often act in immunity (108). Thus, future research is needed to validate

709 the results and reveal if the difference in the transcriptomic results obtained for the two house finch
710 tissues reflect true biological difference between the tissues, variation in the transcriptomic approaches
711 adopted, or both.

712

713 Conclusion

714 Our results illuminate potential immunological pathways underlying increased tolerance to MG in birds
715 from the VA population compared to the other house finch populations. Notably, they suggest the
716 importance of evolving balance between the Th1 and Th17 pathway activation during the initial
717 conjunctival response of the house finches to the MG infection. The populations in no or only recent
718 contact with MG may have increased tendency for up-regulation of the *IL17*-linked pathway (observed
719 in AZ), while the populations with long-established co-evolutionary history with MG (VA), could
720 promote *IL12* signalling to increase Th1 and/or anti-inflammatory (possibly B-cell driven) immune
721 responses. Further research should focus on understanding of specific roles of various cell types in the
722 immune responses to MG in birds from populations differing in their co-evolutionary history with MG.
723 Furthermore, our results also document that infection with a more recent MG isolate (VA2013) triggers
724 in conjunctiva stronger expression of immune genes than infection with the original isolate (VA1994).
725 Since also non-immune pathways may be affected by this regulation (e.g. pathways regulating the extent
726 of the sickness behaviour which influence MG transmission in the finches; 36,109), further research
727 should also investigate the expression changes in genes with other than immune functions expressed in
728 other than lymphoid tissues.

729 Acknowledgement

730 We would like to thank all the research assistants that helped with the field work (especially Marissa
731 Langager and Allison Rowley) and the subsequent laboratory analysis. We are also grateful to P. Hutton
732 and K. McGraw (Arizona State University), and S. Goldstein, P. Howard, and J. Omick (Hawaii USDA)
733 for their help with logistics in the field. The birds were trapped and the experiment was performed within
734 the framework of the project No. 1755197 (Iowa State University), NSF 1950307 (University of
735 Memphis) and No. 1754872 (Virginia Tech) (title ‘Collaborative Research: Immune mechanisms and
736 epidemiological consequences of tolerance in a naturally occurring host-pathogen system’) supported
737 by the U.S. National Science Foundation. This study was supported by the Grant Schemes at Charles
738 University (grant nos. GAUK 646119 and START/SCI/113 with reg. no.
739 CZ.02.2.69/0.0/0.0/19_073/0016935) and by the Ministry of Education, Youth and Sports of the Czech
740 Republic (INTER-ACTION grant no. LUAUS24184. Computational resources and data storage were
741 provided by the Czech Education and Scientific NETwork (CESNET; project e-INFRA CZ LM2018140
742 supported by the Ministry of Education, Youth and Sports of the Czech Republic). The study was further
743 supported by the Institutional Research Support No. 260684/2023.

744

745 Author contributions

746 Conceptualization: NKV, AEH, RAD, DMH, JSA, MV

747 Data Curation: NKV, AEH, DMH, JSA

748 Formal Analysis: NKV, BM

749 Funding Acquisition: NKV, BM, RAD, DMH, JSA

750 Investigation: NKV, AEH, BM, RAD, DMH, JSA, MV
751 Methodology: NKV, AEH, BM, VB, RAD, DMH, JSA, MV
752 Project Administration: NKV, BM, AEH, DMH, JSA, MV
753 Resources: MV, RAD, DMH, JSA
754 Software: n/a
755 Supervision: AEH, RAD, DMH, JSA, MV
756 Validation: NKV, AEH, RAD, DMH, JSA, MV
757 Visualization: NKV
758 Writing – Original Draft Preparation: NKV, MV
759 Writing – Review and Editing: NKV, AEH, BM, RAD, VB, DMH, JSA, MV

760 **Ethics statement**

761 All animal work was approved by the Institutional Animal Care and Use Committees (IACUC) at Iowa
762 State University (ISU) and Virginia Tech, and the ISU Institutional Biosafety Committee with
763 appropriate permissions provided by state and federal agencies.

764 **References**

765

- 766 1. Woolhouse ME, Webster JP, Domingo E, Charlesworth B, Levin BR. Biological and biomedical
767 implications of the co-evolution of pathogens and their hosts. *Nat Genet* (2002) 32:569–577.
- 768 2. Read AF. The evolution of virulence. *Trends Microbiol* (1994) 2:73–76.
- 769 3. Bloom DE, Black S, Rappuoli R. Emerging infectious diseases: A proactive approach. *Proc Natl
770 Acad Sci* (2017) 114:4055–4059.
- 771 4. Cunningham AA, Daszak P, Wood JL. One Health, emerging infectious diseases and wildlife: two
772 decades of progress? *Philos Trans R Soc B Biol Sci* (2017) 372:20160167.
- 773 5. Hawley DM, Osnas EE, Dobson AP, Hochachka WM, Ley DH, Dhondt AA. Parallel patterns of
774 increased virulence in a recently emerged wildlife pathogen. *PLoS Biol* (2013) 11:e1001570.
- 775 6. Voyles J, Woodhams DC, Saenz V, Byrne AQ, Perez R, Rios-Sotelo G, Ryan MJ, Bletz MC, Sobell
776 FA, McLetchie S. Shifts in disease dynamics in a tropical amphibian assemblage are not due to
777 pathogen attenuation. *Science* (2018) 359:1517–1519.
- 778 7. Langwig KE, Hoyt JR, Parise KL, Frick WF, Foster JT, Kilpatrick AM. Resistance in persisting bat
779 populations after white-nose syndrome invasion. *Philos Trans R Soc B Biol Sci* (2017)
780 372:20160044.
- 781 8. Alves JM, Carneiro M, Cheng JY, Lemos de Matos A, Rahman MM, Loog L, Campos PF, Wales N,
782 Eriksson A, Manica A. Parallel adaptation of rabbit populations to myxoma virus. *Science* (2019)
783 363:1319–1326.

784 9. Graham AL, Allen JE, Read AF. Evolutionary causes and consequences of immunopathology.
785 *Annu Rev Ecol Evol Syst* (2005) 36:373–397.

786 10. Seal S, Dharmarajan G, Khan I. Evolution of pathogen tolerance and emerging infections: A
787 missing experimental paradigm. *Elife* (2021) 10:e68874.

788 11. Boots M, Bowers RG. Three mechanisms of host resistance to microparasites—avoidance,
789 recovery and tolerance—show different evolutionary dynamics. *J Theor Biol* (1999) 201:13–23.

790 12. Råberg L, Sim D, Read AF. Disentangling genetic variation for resistance and tolerance to
791 infectious diseases in animals. *Science* (2007) 318:812–814.

792 13. Miller MR, White A, Boots M. THE EVOLUTION OF PARASITES IN RESPONSE TO TOLERANCE IN
793 THEIR HOSTS: THE GOOD, THE BAD, AND APPARENT COMMENSALISM. *Evolution* (2006)
794 60:945–956. doi: 10.1111/j.0014-3820.2006.tb01173.x

795 14. Little TJ, Shuker DM, Colegrave N, Day T, Graham AL. The coevolution of virulence: tolerance in
796 perspective. *PLoS Pathog* (2010) 6:e1001006.

797 15. Henschen AE, Adelman JS. What does tolerance mean for animal disease dynamics when
798 pathology enhances transmission? *Integr Comp Biol* (2019) 59:1220–1230.

799 16. Ruden RM, Adelman JS. Disease tolerance alters host competence in a wild songbird. *Biol Lett*
800 (2021) 17:20210362.

801 17. Savage AE, Zamudio KR. Adaptive tolerance to a pathogenic fungus drives major
802 histocompatibility complex evolution in natural amphibian populations. *Proc R Soc B Biol Sci*
803 (2016) 283:20153115.

804 18. Atkinson CT, Saili KS, Utzurrum RB, Jarvi SI. Experimental evidence for evolved tolerance to
805 avian malaria in a wild population of low elevation Hawai ‘i ‘Amakihi (*Hemignathus virens*).
806 *EcoHealth* (2013) 10:366–375.

807 19. Weber JN, Steinel NC, Peng F, Shim KC, Lohman BK, Fuess LE, Subramanian S, Lisle SPD, Bolnick
808 DI. Evolutionary gain and loss of a pathological immune response to parasitism. *Science* (2022)
809 377:1206–1211.

810 20. Henschen AE, Vinkler M, Langager MM, Rowley AA, Dalloul RA, Hawley DM, Adelman JS. Rapid
811 adaptation to a novel pathogen through disease tolerance in a wild songbird. *PLoS Pathog*
812 (2023) 19:e1011408.

813 21. Vinkler M, Fiddaman SR, Těšický M, O’Connor EA, Savage AE, Lenz TL, Smith AL, Kaufman J,
814 Bolnick DI, Davies CS, et al. Understanding the evolution of immune genes in jawed vertebrates.
815 *J Evol Biol* (2023) 36:847–873. doi: 10.1111/jeb.14181

816 22. Ley DH, Yoder Jr H. *Mycoplasma gallisepticum* infection In: Diseases of poultry. (2008)

817 23. Ferguson-Noel N, Armour NK, Noormohammadi AH, El-Gazzar M, Bradbury JM. Mycoplasmosis.
818 *Dis Poult* (2020)907–965.

819 24. Ley DH, Berkhoff JE, McLaren JM. *Mycoplasma gallisepticum* Isolated from House Finches
820 (*Carpodacus mexicanus*) with Conjunctivitis. *Avian Dis* (1996) 40:480. doi: 10.2307/1592250

821 25. Dhondt AA, Altizer S, Cooch EG, Davis AK, Dobson A, Driscoll MJL, Hartup BK, Hawley DM,
822 Hochachka WM, Hosseini PR, et al. Dynamics of a novel pathogen in an avian host:
823 Mycoplasmal conjunctivitis in house finches. *Acta Trop* (2005) 94:77–93. doi:
824 10.1016/j.actatropica.2005.01.009

825 26. Faustino CR, Jennelle CS, Connolly V, Davis AK, Swarthout EC, Dhondt AA, Cooch EG.
826 Mycoplasma gallisepticum infection dynamics in a house finch population: seasonal variation in
827 survival, encounter and transmission rate. *J Anim Ecol* (2004) 73:651–669.

828 27. Hochachka WM, Dhondt AA. Density-dependent decline of host abundance resulting from a
829 new infectious disease. *Proc Natl Acad Sci* (2000) 97:5303–5306.

830 28. Staley M, Bonneau C, McGraw KJ, Vleck CM, Hill GE. Detection of Mycoplasma gallisepticum in
831 house finches (*Haemorhous mexicanus*) from Arizona. *Avian Dis* (2018) 62:14–17.

832 29. Ley DH, Hawley DM, Geary SJ, Dhondt AA. House Finch (*Haemorhous mexicanus*)
833 Conjunctivitis, and *Mycoplasma* spp. Isolated from North American Wild Birds, 1994–2015. *J*
834 *Wildl Dis* (2016) 52:669–673. doi: 10.7589/2015-09-244

835 30. Grodio JL, Hawley DM, Osnas EE, Ley DH, Dhondt KV, Dhondt AA, Schat KA. Pathogenicity and
836 immunogenicity of three Mycoplasma gallisepticum isolates in house finches (*Carpodacus*
837 *mexicanus*). *Vet Microbiol* (2012) 155:53–61. doi: 10.1016/j.vetmic.2011.08.003

838 31. Hawley DM, Dhondt KV, Dobson AP, Grodio JL, Hochachka WM, Ley DH, Osnas EE, Schat KA,
839 Dhondt AA. Common garden experiment reveals pathogen isolate but no host genetic diversity
840 effect on the dynamics of an emerging wildlife disease: Host genetic diversity and disease
841 resistance. *J Evol Biol* (2010) 23:1680–1688. doi: 10.1111/j.1420-9101.2010.02035.x

842 32. Hill GE, Farmer KL. Carotenoid-based plumage coloration predicts resistance to a novel parasite
843 in the house finch. *Naturwissenschaften* (2005) 92:30–34. doi: 10.1007/s00114-004-0582-0

844 33. Adelman JS, Kirkpatrick L, Grodio JL, Hawley DM. House Finch Populations Differ in Early
845 Inflammatory Signaling and Pathogen Tolerance at the Peak of *Mycoplasma gallisepticum*
846 Infection. *Am Nat* (2013) 181:674–689. doi: 10.1086/670024

847 34. Razin S, Yoge D, Naot Y. Molecular Biology and Pathogenicity of Mycoplasmas. *MICROBIOL*
848 *MOL BIOL REV* (1998) 62:63.

849 35. Atkinson TP, Waites KB. *Mycoplasma pneumoniae* infections in childhood. *Pediatr Infect Dis J*
850 (2014) 33:92–94.

851 36. Hawley DM, Thomason CA, Aberle MA, Brown R, Adelman JS. High virulence is associated with
852 pathogen spreadability in a songbird–bacterial system. *R Soc Open Sci* (2023) 10:220975.

853 37. Vinkler M, Leon AE, Kirkpatrick L, Dalloul RA, Hawley DM. Differing House Finch Cytokine
854 Expression Responses to Original and Evolved Isolates of *Mycoplasma gallisepticum*. *Front*
855 *Immunol* (2018) 9:13. doi: 10.3389/fimmu.2018.00013

856 38. Hawley DM, Osnas EE, Dobson AP, Hochachka WM, Ley DH, Dhondt AA. Parallel Patterns of
857 Increased Virulence in a Recently Emerged Wildlife Pathogen. *PLOS Biol* (2013) 11:11.

858 39. Bonneau C, Balenger SL, Russell AF, Zhang J, Hill GE, Edwards SV. Rapid evolution of disease
859 resistance is accompanied by functional changes in gene expression in a wild bird. *Proc Natl
860 Acad Sci* (2011) 108:7866–7871. doi: 10.1073/pnas.1018580108

861 40. Bonneau C, Balenger SL, Zhang J, Edwards SV, Hill GE. Innate immunity and the evolution of
862 resistance to an emerging infectious disease in a wild bird: EVOLUTION OF RESISTANCE: ROLE
863 OF INNATE IMMUNITY. *Mol Ecol* (2012) 21:2628–2639. doi: 10.1111/j.1365-294X.2012.05551.x

864 41. Pyle P. Molt limits in North American passerines. *North Am Bird Bander* (1997) 22:49–89.

865 42. Fleming-Davies AE, Williams PD, Dhondt AA, Dobson AP, Hochachka WM, Leon AE, Ley DH,
866 Osnas EE, Hawley DM. Incomplete host immunity favors the evolution of virulence in an
867 emergent pathogen. *Science* (2018) 359:1030–1033.

868 43. Corley SM, Troy NM, Bosco A, Wilkins MR. QuantSeq. 3' Sequencing combined with Salmon
869 provides a fast, reliable approach for high throughput RNA expression analysis. *Sci Rep* (2019)
870 9:18895. doi: 10.1038/s41598-019-55434-x

871 44. Jarvis S, Birsa N, Secrier M, Fratta P, Plagnol V. A Comparison of Low Read Depth QuantSeq 3'
872 Sequencing to Total RNA-Seq in FUS Mutant Mice. *Front Genet* (2020) 11:1412. doi:
873 10.3389/fgene.2020.562445

874 45. Moll P, Ante M, Seitz A, Reda T. QuantSeq 3' mRNA sequencing for RNA quantification. *Nat
875 Methods* (2014) 11:i–iii. doi: 10.1038/nmeth.f.376

876 46. Zhong S, Joung J-G, Zheng Y, Chen Y, Liu B, Shao Y, Xiang JZ, Fei Z, Giovannoni JJ. High-
877 throughput illumina strand-specific RNA sequencing library preparation. *Cold Spring Harb
878 Protoc* (2011) 2011:pdb-prot5652.

879 47. Ma F, Fuqua BK, Hasin Y, Yukhtman C, Vulpe CD, Lusis AJ, Pellegrini M. A comparison between
880 whole transcript and 3' RNA sequencing methods using Kapa and Lexogen library preparation
881 methods. *BMC Genomics* (2019) 20:9. doi: 10.1186/s12864-018-5393-3

882 48. Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG,
883 Bennett R, Bhai J, et al. Ensembl 2021. *Nucleic Acids Res* (2021) 49:D884–D891. doi:
884 10.1093/nar/gkaa942

885 49. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.
886 *Bioinformatics* (2014) 30:2114–2120.

887 50. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR.
888 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* (2013) 29:15–21.

889 51. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning
890 sequence reads to genomic features. *Bioinformatics* (2014) 30:923–930. doi:
891 10.1093/bioinformatics/btt656

892 52. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential
893 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015)
894 43:e47–e47. doi: 10.1093/nar/gkv007

895 53. Team RC. R: A language and environment for statistical computing [Internet]. R Foundation for
896 Statistical Computing; 2018. Available [Http://www.R-Proj.OrgGoogle Sch](http://www.R-Proj.OrgGoogle Sch) (2020)

897 54. Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants.
898 *Bioinformatics* (2020) 36:2628–2629. doi: 10.1093/bioinformatics/btz931

899 55. Kaspers B, Schat KA, Göbel T, Vervelde L. *Avian immunology*. Academic Press (2021).

900 56. Culhane AC, Perriere G, Considine EC, Cotter TG, Higgins DG. Between-group analysis of
901 microarray data. *Bioinformatics* (2002) 18:1600–1608.

902 57. Wu R, Kang R, Tang D. Mitochondrial ACOD1/IRG1 in infection and sterile inflammation. *J
903 Intensive Med* (2022)

904 58. Guo D, Dong W, Cong Y, Liu Y, Liang Y, Ye Z, Zhang J, Zhou Y. LIF Aggravates Pulpitis by
905 Promoting Inflammatory Response in Macrophages. *Inflammation* (2023)1–16.

906 59. Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between
907 immune and nervous systems. *Front Cell Neurosci* (2014) 8:65.

908 60. Wu R, Chen F, Wang N, Tang D, Kang R. ACOD1 in immunometabolism and disease. *Cell Mol
909 Immunol* (2020) 17:822–833. doi: 10.1038/s41423-020-0489-5

910 61. Lee Y, Clinton J, Yao C, Chang SH. Interleukin-17D promotes pathogenicity during infection by
911 suppressing CD8 T cell activity. *Front Immunol* (2019) 10:1172.

912 62. Zhu C, Chen X, Guan G, Zou C, Guo Q, Cheng P, Cheng W, Wu A. IFI30 is a novel immune-related
913 target with predicting value of prognosis and treatment response in glioblastoma. *OncoTargets
914 Ther* (2020) 13:1129.

915 63. Chen Y, Zhao H, Feng Y, Ye Q, Hu J, Guo Y, Feng Y. Pan-cancer analysis of the associations of
916 TGFBI expression with prognosis and immune characteristics. *Front Mol Biosci* (2021) 8:745649.

917 64. de Almeida LA, Macedo GC, Marinho FA, Gomes MT, Corsetti PP, Silva AM, Cassataro J,
918 Giambartolomei GH, Oliveira SC. Toll-like receptor 6 plays an important role in host innate
919 resistance to *Brucella abortus* infection in mice. *Infect Immun* (2013) 81:1654–1662.

920 65. Kulappu Arachchige SN, Young ND, Kanci Condello A, Omotainse OS, Noormohammadi AH,
921 Wawegama NK, Browning GF. Transcriptomic analysis of long-term protective immunity
922 induced by vaccination with *Mycoplasma gallisepticum* strain ts-304. *Front Immunol* (2021)
923 11:628804.

924 66. Beaudet J, Tulman E, Pflaum K, Liao X, Kutish G, Szczepanek S, Silburt L, Geary S. Transcriptional
925 profiling of the chicken tracheal response to virulent *Mycoplasma gallisepticum* strain Rlow.
926 *Infect Immun* (2017) 85:e00343-17.

927 67. Tian W, Zhao C, Hu Q, Sun J, Peng X. Roles of Toll-like receptors 2 and 6 in the inflammatory
928 response to *Mycoplasma gallisepticum* infection in DF-1 cells and in chicken embryos. *Dev
929 Comp Immunol* (2016) 59:39–47. doi: 10.1016/j.dci.2016.01.008

930 68. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II
931 function. *Biochim Biophys Acta BBA - Mol Cell Res* (2002) 1542:1–13. doi: 10.1016/S0167-
932 4889(01)00166-5

933 69. David K, Friedlander G, Pellegrino B, Radomir L, Lewinsky H, Leng L, Bucala R, Becker-Herman S,
934 Shachar I. CD74 as a regulator of transcription in normal B cells. *Cell Rep* (2022) 41:111572. doi:
935 10.1016/j.celrep.2022.111572

936 70. Fukuda Y, Bustos MA, Cho S-N, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DS.
937 Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor
938 growth and influences patient survival in melanoma. *Cell Death Dis* (2022) 13:117.

939 71. Mohammed J, Frasca Jr S, Cecchini K, Rood D, Nyaoke AC, Geary SJ, Silburt LK. Chemokine and
940 cytokine gene expression profiles in chickens inoculated with *Mycoplasma gallisepticum* strains
941 Rlow or GT5. *Vaccine* (2007) 25:8611–8621.

942 72. Gehring T, Seeholzer T, Krappmann D. BCL10 – Bridging CARDs to Immune Activation. *Front
943 Immunol* (2018) 9:1539. doi: 10.3389/fimmu.2018.01539

944 73. Willis TG, Jadayel DM, Du M-Q, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L,
945 Majekodunmi O, Wlodarska I. Bcl10 is involved in t (1; 14)(p22; q32) of MALT B cell lymphoma
946 and mutated in multiple tumor types. *Cell* (1999) 96:35–45.

947 74. Costanzo A, Guiet C, Vito P. c-E10 is a caspase-recruiting domain-containing protein that
948 interacts with components of death receptors signaling pathway and activates nuclear factor-
949 κB. *J Biol Chem* (1999) 274:20127–20132.

950 75. Koseki T, Inohara N, Chen S, Carrio R, Merino J, Hottiger MO, Nabel GJ, Núñez G. CIPER, a novel
951 NF κB-activating protein containing a caspase recruitment domain with homology to
952 herpesvirus-2 protein E10. *J Biol Chem* (1999) 274:9955–9961.

953 76. Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, Millar DG, Bouchard D,
954 Wakeham A, Ohashi PS, et al. Bcl10 Is a Positive Regulator of Antigen Receptor–Induced
955 Activation of NF-κ B and Neural Tube Closure. *Cell* (2001) 104:33–42. doi: 10.1016/S0092-
956 8674(01)00189-1

957 77. Garcia-Solis B, Van Den Rym A, Pérez-Caraballo JJ, Al-Ayoubi A, Alazami AM, Lorenzo L,
958 Cubillos-Zapata C, López-Collazo E, Pérez-Martínez A, Allende LM. Clinical and immunological
959 features of human BCL10 deficiency. *Front Immunol* (2021)4732.

960 78. Murphy JT, Sommer S, Kabara EA, Verman N, Kuelbs MA, Saama P, Halgren R, Coussens PM.
961 Gene expression profiling of monocyte-derived macrophages following infection with
962 *Mycobacterium avium* subspecies *avium* and *Mycobacterium avium* subspecies
963 *paratuberculosis*. *Physiol Genomics* (2006) 28:67–75.

964 79. Wang Y, Miao X, Li H, Su P, Lin L, Liu L, Li X. The correlated expression of immune and energy
965 metabolism related genes in the response to *Salmonella enterica* serovar *Enteritidis* inoculation
966 in chicken. *BMC Vet Res* (2020) 16:1–9.

967 80. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J. Bcl10 and Malt1 control
968 lysophosphatidic acid-induced NF-κB activation and cytokine production. *Proc Natl Acad Sci*
969 (2007) 104:134–138.

970 81. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses
971 and host defense against pathogens. *Immunol Rev* (2008) 226:57–79.

972 82. Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and
973 therapy of psoriasis. *J Dermatol Sci* (2012) 65:4–11.

974 83. Luo C, Qu H, Ma J, Wang J, Hu X, Li N, Shu D. A genome-wide association study identifies major
975 loci affecting the immune response against infectious bronchitis virus in chicken. *Infect Genet
976 Evol* (2014) 21:351–358. doi: 10.1016/j.meegid.2013.12.004

977 84. de Paiva CS, Leger AJS, Caspi RR. Mucosal immunology of the ocular surface. *Mucosal Immunol
978* (2022) 15:1143–1157.

979 85. Bialasiewicz AA, Schaudig U, Ma J-X, Vieth S, Richard G. α/β -and γ/δ -T cell-receptor-positive
980 lymphocytes in healthy and inflamed human conjunctiva. *Graefes Arch Clin Exp Ophthalmol
981* (1996) 234:467–471.

982 86. Arnous R, Arshad S, Sandgren K, Cunningham AL, Carnt N, White A. Tissue resident memory T
983 cells inhabit the deep human conjunctiva. *Sci Rep* (2022) 12:6077.

984 87. Li L, Li Y, Zhu X, Wu B, Tang Z, Wen H, Yuan J, Zheng Q, Chen W. Conjunctiva resident $\gamma\delta$ T cells
985 expressed high level of IL-17A and promoted the severity of dry eye. *Invest Ophthalmol Vis Sci
986* (2022) 63:13–13.

987 88. Gaudet P, Livstone MS, Lewis SE, Thomas PD. Phylogenetic-based propagation of functional
988 annotations within the Gene Ontology consortium. *Brief Bioinform* (2011) 12:449–462.

989 89. Wildenberg ME, van den Brink GR. FXR activation inhibits inflammation and preserves the
990 intestinal barrier in IBD. *Gut* (2011) 60:432–433.

991 90. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a
992 modulator of intestinal innate immunity. *J Immunol* (2009) 183:6251–6261.

993 91. Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA,
994 Repa JJ. Regulation of antibacterial defense in the small intestine by the nuclear bile acid
995 receptor. *Proc Natl Acad Sci* (2006) 103:3920–3925.

996 92. Hickman-Davis JM. Role of innate immunity in respiratory mycoplasma infection. *Front Biosci-
997 Landmark* (2002) 7:1347–1355.

998 93. Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, Li N, Wei F. Regulation of IL-10 and IL-12
999 production and function in macrophages and dendritic cells. *F1000Research* (2015) 4:

1000 94. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K. Novel
1001 p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well
1002 as distinct from IL-12. *Immunity* (2000) 13:715–725.

1003 95. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L, Cooper AM, Cua DJ. IL-12 and IL-
1004 23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory
1005 diseases. *Nat Med* (2015) 21:719–729.

1006 96. Wassink L, Vieira PL, Smits HH, Kingsbury GA, Coyle AJ, Kapsenberg ML, Wierenga EA. ICOS
1007 Expression by Activated Human Th Cells Is Enhanced by IL-12 and IL-23: Increased ICOS
1008 Expression Enhances the Effector Function of Both Th1 and Th2 Cells. *J Immunol* (2004)
1009 173:1779–1786. doi: 10.4049/jimmunol.173.3.1779

1010 97. Chen D, Tang T-X, Deng H, Yang X-P, Tang Z-H. Interleukin-7 biology and its effects on immune
1011 cells: mediator of generation, differentiation, survival, and homeostasis. *Front Immunol*
1012 (2021)5156.

1013 98. Li C, Corraliza I, Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in
1014 *Plasmodium chabaudi chabaudi* infection in mice. *Infect Immun* (1999) 67:4435–4442.

1015 99. Siewe L, Bollati–Fogolin M, Wickenhauser C, Krieg T, Müller W, Roers A. Interleukin-10 derived
1016 from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the
1017 response to CpG DNA. *Eur J Immunol* (2006) 36:3248–3255.

1018 100. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute
1019 influenza virus infection by producing IL-10. *Nat Med* (2009) 15:277–284.

1020 101. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. Resolution
1021 of a chronic viral infection after interleukin-10 receptor blockade. *J Exp Med* (2006) 203:2461–
1022 2472.

1023 102. Kurata S, Osaki T, Yonezawa H, Arae K, Taguchi H, Kamiya S. Role of IL-17A and IL-10 in the
1024 antigen induced inflammation model by *Mycoplasma pneumoniae*. *BMC Microbiol* (2014) 14:1–
1025 11.

1026 103. Ihim SA, Abubakar SD, Zian Z, Sasaki T, Saffarioun M, Maleknia S, Azizi G. Interleukin-18
1027 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation,
1028 and treatment. *Front Immunol* (2022)4470.

1029 104. Chen C, Li J, Zhang W, Shah SWA, Ishfaq M. *Mycoplasma gallisepticum* triggers immune damage
1030 in the chicken thymus by activating the TLR-2/MyD88/NF- κ B signaling pathway and NLRP3
1031 inflammasome. *Vet Res* (2020) 51:1–13.

1032 105. Arshad T, Mansur F, Palek R, Manzoor S, Liska V. A double edged sword role of interleukin-22 in
1033 wound healing and tissue regeneration. *Front Immunol* (2020) 11:2148.

1034 106. Gupta SK, Parlane N, Bridgeman B, Lynch AT, Dangerfield EM, Timmer MS, Stocker BL, Wedlock
1035 DN. The trehalose glycolipid C18Brar promotes antibody and T-cell immune responses to
1036 *Mannheimia haemolytica* and *Mycoplasma ovipneumoniae* whole cell antigens in sheep. *PloS
1037 One* (2023) 18:e0278853.

1038 107. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev
1039 Genet* (2009) 10:57–63. doi: 10.1038/nrg2484

1040 108. Vo TTM, Nguyen TV, Amoroso G, Ventura T, Elizur A. Deploying new generation sequencing for
1041 the study of flesh color depletion in Atlantic Salmon (*Salmo salar*). *BMC Genomics* (2021)
1042 22:545. doi: 10.1186/s12864-021-07884-9

1043 109. Bouwman KM, Hawley DM. Sickness behaviour acting as an evolutionary trap? Male house
1044 finches preferentially feed near diseased conspecifics. *Biol Lett* (2010) 6:462–465.

1045

1046